G
Gordon H. Guyatt
Researcher at McMaster University
Publications - 1749
Citations - 262329
Gordon H. Guyatt is an academic researcher from McMaster University. The author has contributed to research in topics: Randomized controlled trial & Medicine. The author has an hindex of 231, co-authored 1620 publications receiving 228631 citations. Previous affiliations of Gordon H. Guyatt include Memorial Sloan Kettering Cancer Center & Cayetano Heredia University.
Papers
More filters
Journal ArticleDOI
Medical cannabis or cannabinoids for chronic pain: a clinical practice guideline.
Jason W. Busse,Patrick Vankrunkelsven,Linan Zeng,Linan Zeng,Anja Fog Heen,Arnaud Merglen,Fiona Campbell,Lars-Petter Granan,Bert Aertgeerts,Bert Aertgeerts,Rachelle Buchbinder,Matteo Coen,Matteo Coen,David N. Juurlink,David N. Juurlink,Caroline Flora Samer,Caroline Flora Samer,Reed A C Siemieniuk,Nimisha Kumar,Lynn Cooper,John Brown,Lyubov Lytvyn,Dena Zeraatkar,Dena Zeraatkar,Li Wang,Gordon H. Guyatt,Per Olav Vandvik,Thomas Agoritsas +27 more
TL;DR: In this paper, a guideline expert panel issued a weak recommendation to offer a trial of non-inhaled medical cannabis or cannabinoids, in addition to standard care and management (if not sufficient), for people living with chronic cancer or non-cancer pain.
Journal ArticleDOI
DNR directives are established early in mechanically ventilated intensive care unit patients.
Tasnim Sinuff,Deborah J. Cook,Graeme Rocker,Lauren Griffith,Stephen D. Walter,M. McD. Fisher,Peter Dodek,Peter Sjokvist,Ellen McDonald,John C. Marshall,Peter A. Kraus,Mitchell M. Levy,Neil M. Lazar,Gordon H. Guyatt +13 more
TL;DR: One third of mechanically ventilated patients had DNR directives established early during their ICU stay after the first 24 hr of admission, and the strongest predictors were physician prediction of low probability of survival, physician perception of patient preference to limit life support, organ dysfunction, medical diagnosis and age.
Journal ArticleDOI
SGLT-2 inhibitors or GLP-1 receptor agonists for adults with type 2 diabetes: a clinical practice guideline
Sheyu Li,Per Olav Vandvik,Lyubov Lytvyn,Gordon H. Guyatt,Suetonia C. Palmer,Rene Rodriguez-Gutierrez,Rene Rodriguez-Gutierrez,Farid Foroutan,Thomas Agoritsas,Reed A C Siemieniuk,Michael Walsh,Lawrie Frere,David J. Tunnicliffe,David J. Tunnicliffe,Evi V. Nagler,Veena Manja,Bjørn Olav Åsvold,Vivekanand Jha,Vivekanand Jha,Mieke Vermandere,Karim Gariani,Qian Zhao,Yan Ren,Emma Cartwright,Patrick Gee,Alan Wickes,Linda Ferns,Robin Wright,Ling Li,Qiukui Hao,Qiukui Hao,Reem A. Mustafa,Reem A. Mustafa +32 more
TL;DR: The guideline panel issued risk-stratified recommendations concerning the use of SGLT-2 inhibitors or GLP-1 receptor agonists in adults with type 2 diabetes as mentioned in this paper.
Journal Article
A review of heart failure treatment.
TL;DR: There is now overwhelming evidence that beta-blockers are safe for heart failure patients but that they reduce the risk of death for these patients by approximately 30%.
Journal ArticleDOI
Arthroscopic surgery for knee pain
TL;DR: A highly questionable practice without supporting evidence of even moderate quality that may or may not be harmful to humans.